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BACKGROUND. Health-related quality of life (HRQOL) has not been adequately measured
in bladder cancer. A recently developed reliable and disease-specific quality of life instru-
ment (Bladder Cancer Index, BCI) was used to measure urinary, sexual, and bowel func-
tion and bother domains in patients with bladder cancer managed with several different
interventions, including cystectomy and endoscopic-based procedures.
METHODS. Patients with bladder cancer were identified from a prospective bladder can-
cer outcomes database and contacted as part of an Institutional Review Board-approved
study to assess treatment impact onHRQOL. HRQOLwasmeasured using the BCI across
stratified treatment groups. Bivariate and multivariable analyses adjusted for age, gender,
income, education, relationship status, and follow-up time were performed to compare
urinary, bowel, and sexual domains between treatment groups.
RESULTS. In all, 315 bladder cancer patients treated at the University of Michigan com-
pleted the BCI in 2004. Significant differences were seen in mean BCI function and
bother scores between cystectomy and native bladder treatment groups. In addition,
urinary function scores were significantly lower among cystectomy patients treated
with continent neobladder compared with those treated with ileal conduit (all pair-
wise P<.05).
CONCLUSIONS. The BCI is responsive to functional and bother differences in patients
with bladder cancer treated with different surgical approaches. Significant differences
between therapy groups in each of the urinary, bowel, and sexual domains exist.
Among patients treated with orthotopic continent urinary diversion, functional
impairments related to urinary incontinence and lack of urinary control account
for the low observed urinary function scores. Cancer 2007;109:1756–62.  2007
American Cancer Society.
KEYWORDS: bladder cancer, health-related quality of life assessment, cancer
outcomes.
F or patients diagnosed and treated for bladder cancer, disease- andtreatment-specific effects can have a substantial impact on func-
tional outcomes and health-related quality of life (HRQOL). In
patients treated with radical cystectomy and urinary diversion, these
concerns are particularly relevant given the long-term effects on uri-
nary, gastrointestinal, and sexual functioning, as well as potential
changes in body image. As a result, there has been considerable effort
directed toward limiting the functional and HRQOL impairments
associated with cystectomy and urinary diversion, primarily through
surgical advances such as continent urinary diversion.1,2
Despite the long-recognized need for HRQOL assessment among
this group of patients, a lack of reliable and sensitive measures has lim-
ited research in this area. Furthermore, the focus of this work has largely
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excluded the majority of patients with bladder cancer
whose disease is not managed with cystectomy. As there
are few validated HRQOL measures that are specific for
bladder cancer,3 and those that do exist are limited to
patients treated with cystectomy,4 little is known regard-
ing the burden of disease and treatment among this pre-
valent group. Consequently, the full extent of disease
and treatment effects has not been adequately meas-
ured among the overall bladder cancer population.
Given these limitations, we developed and validated
a reliable and disease-specific instrument known as the
Bladder Cancer Index (BCI) to evaluate HRQOL in a
wide range of patients with bladder cancer.5 The objec-
tive of this study was to assess the ability of the BCI to
detect disease-specific HRQOL differences among a
diverse group of bladder cancer patients managed with




After Institutional Review Board approval, patients with
bladder cancer were identified from a prospective insti-
tutional bladder cancer database and contacted regard-
ing study participation. Study participants included
patients diagnosed and treated for bladder cancer at the
University of Michigan between 1995 and 2004. The
study sample was not limited by age, gender, disease
stage, or previous treatments, and included patients
managed with various treatment modalities, including
cystoscopy alone, cystoscopy with intravesical therapy,
radical cystectomy with ileal conduit diversion, and rad-
ical cystectomy with neobladder diversion. Because
orthotopic diversions are the preferred method of conti-
nent urinary diversion at the University of Michigan,
nonorthotopic continent urinary diversions were not
commonly performed during the study period and were
therefore not included in the analysis. The BCI ques-
tionnaire, consent form, and instructions were mailed
to study participants for completion and then returned
to the University of Michigan Medical Center for ques-
tionnaire scoring and data collection.
HRQOL Assessment
The BCI is a reliable, disease-specific HRQOL instru-
ment developed using standard psychometric method-
ology and has been evaluated with test-retest validity,
internal consistency, and divergent/convergent validity
in multiple performance phases.5 The index consists of
34 items within 3 primary domains measuring urinary,
bowel, and sexual health, and 2 subdomains (function
and bother) for each primary domain. For patients man-
aged with an ileal conduit urinary diversion, BCI urinary
items assess stoma and appliance function, and are
designed to measure symptoms such as urinary leakage
and skin irritation that may result from suboptimal
stomal placement, retraction, and appliance fit. Item
responses are based on Likert scales, with domain and
subdomain scores standardized to a 0–100 point scale
where higher scores correspond to better health states.
Outcome Measures
HRQOL assessments were performed at a single time af-
ter bladder cancer treatment using the BCI. The primary
outcome measures included function and bother scores
for each BCI domain (urinary, bowel, and sexual).
Statistical Analysis
Cases were stratified into 4 groups according to treat-
ment type: 1) native bladder, no treatment with intra-
vesical therapy; 2) native bladder, treatment with
intravesical therapy; 3) cystectomy with ileal conduit
urinary diversion; and 4) cystectomy with neobladder
urinary diversion. Urinary, bowel, and sexual function
and bother scores were compared between treatment
groups in 2 ways: bivariate comparisons were per-
formed using analysis of variance (ANOVA); and multi-
variable comparisons, adjusted for demographic (age,
gender), socioeconomic (income, education level, rela-
tionship status), and clinical (treatment type, follow-up
time) parameters were performed using analysis of
covariance (ANCOVA). Final models were constructed
using a backwards selection method. Tukey multiple
comparison adjustment was used to preserve the overall
error in pairwise assessments. All statistical tests were 2-
tailed and performed at the 5% significance level. Analy-
ses were performed using the SAS System (Cary, NC).
RESULTS
A total of 315 bladder cancer patients treated at the Uni-
versity of Michigan completed the BCI in 2004. Initially,
693 patients were contacted to participate in the study;
of those, 29 were deceased, 36 had no available contact
information, and 313 refused participation, resulting in
a response rate of 45%. The median age was 69 years
(range, 41–89), and the median follow-up period was 2.9
years (range, 0.2–9.8). Complete demographic and clini-
cal information stratified according to treatment group
are presented in Tables 1 and 2, respectively. Patients
treated with cystectomy and neobladder tended to be
younger than other groups; however, age differences
were not significant between groups. Significant differ-
ences did exist for gender, income level, grade, stage,
and presence of carcinoma in situ (CIS). As expected,
the cystectomy groups consisted of significantly higher














n 52 (16.5) 75 (23.8) 66 (21.0) 122 (38.7) 315
Median age, y 72.7 72.5 73.6 64.9
Sex*
Men 36 (69.2) 69 (92.0) 60 (90.9) 93 (76.2) 258 (81.9)
Women 16 (30.8) 6 (8.0) 6 (9.1) 29 (23.8) 57 (18.1)
Race
White 48 (92.3) 69 (93.2) 62 (95.4) 111 (91.0) 290 (92.6)
Black 3 (5.8) 3 (4.1) 2 (3.1) 1 (0.8) 9 (2.9)
Other 1 (1.9) 2 (2.7) 1 (1.5) 10 (8.2) 14 (4.5)
Income level*
30K 35 (70.0) 47 (66.2) 34 (53.1) 88 (76.5) 204 (68.0)
<30K 15 (30.0) 24 (33.8) 30 (46.9) 27 (23.5) 96 (32.0)
Education
College 21 (41.2) 28 (37.3) 20 (30.3) 47 (38.5) 116 (36.9)
High school 24 (47.1) 41 (54.7) 37 (56.1) 68 (55.7) 170 (54.1)
<High school 6 (11.8) 6 (8.0) 9 (13.6) 7 (5.7) 28 (8.9)
Living status
Married/partner 39 (78.0) 63 (84.0) 53 (81.5) 99 (81.2) 254 (81.4)
Single 11 (22.0) 12 (16.0) 12 (18.5) 23 (18.8) 58 (18.6)
Tx indicates transection.
* Significant differences within category between the 4 treatment groups (P .05).
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n 52 (16.5) 75 (23.8) 66 (21.0) 122 (38.7) 315
Stage*
Ta 13 (37.1) 31 (43.7) 3 (5.0) 5 (4.2) 52 (16.5)
T1/Tis 8 (22.9) 37 (52.1) 20 (33.3) 49 (41.2) 114 (36.2)
T2 10 (28.6) 3 (4.2) 31 (51.7) 57 (47.9) 101 (32.1)
T3 3 (8.6) 0 (0) 5 (8.3) 7 (5.9) 15 (4.8)
T4 1 (2.8) 0 (0) 1 (1.7) 1 (0.8) 3 (0.9)
Unknown 30 (9.5)
CIS present* 6 (11.5) 37 (49.3) 35 (53.0) 68 (55.7) 145 (46.4)
Grade*
Low 22 (42.3) 18 (24.0) 3 (4.6) 6 (5.0) 49 (15.6)
High 22 (42.3) 48 (64.0) 51 (78.5) 102 (84.3) 223 (70.8)
Unknown 8 (15.4) 9 (12.0) 11 (16.9) 13 (10.7) 43 (13.6)
Histology
TCC 51 (98.1) 74 (98.7) 62 (93.9) 119 (97.5) 306 (97.1)
Other 1 (1.9) 1 (1.3) 4 (6.1) 3 (2.5) 9 (2.9)
Tx indicates transection; CIS, carcinoma in situ; TCC, transitional cell carcinoma.
* Significant differences within category between treatment groups (P .05).
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stage and grade disease compared with the native blad-
der groups.
Mean BCI scores varied by treatment type as illus-
trated in Table 3. In general, the cystectomy groups dis-
played relatively lower scores compared with native
bladder groups in all of the function and bother sub-
domains. Significant differences were seen between the
urinary function scores for the cystectomy/neobladder
group compared with the other 3 treatment groups (all
pairwise P < .001). Notably, the mean score for this
domain was more than 30 points lower among patients
treated with cystectomy and orthotopic continent urinary
diversion relative to the other groups, exceeding the one-
half standard error convention used to determine clini-
cally significant differences. There were also significant
differences in mean urinary bother scores between the
cystectomy/neobladder group and the 2 native bladder
groups (both P < .01). Both cystectomy groups displayed
significantly lower bother scores in the bowel domain
compared with the native bladder groups (all pairwise
P < .05), and for the sexual domain there were signifi-
cantly lower scores among the 2 cystectomy groups rela-
tive to the native bladder groups in both the function
(SF) and bother (SB) subdomains (all pairwise SF P <
.001; all pairwise SB P<.03). Complete pairwise compari-
sons for adjusted mean domain scores are shown in
Table 3. Adjusting for covariates did not change the
estimatedmean scores (unadjusted scores not shown).
A subanalysis of the response distribution for urinary
function items was performed according to treatment
group given the unexpected but significant differences
observed between cystectomy groups. Figures 1 and 2
illustrate the responses for daytime and nighttime urinary
function questions, respectively. In general, the neoblad-
der group more commonly reported frequent urinary
leakage and occasional urinary dribbling compared with
the other groups, including the ileal conduit group. The
responses for nighttime urinary leakage and lack of
control worsened dramatically in the neobladder group
(Fig. 2); greater than 54% reported urinary leakage every
night and approximately 48% reported no urinary control
or frequent dribbling at night. The proportion of ileal con-
duit patients with these levels of impairment in urinary
function were considerably less (6.7% leakage every night
and 10.2% no urinary control or frequent dribbling at
night). Because orthotopic urinary diversion is often
employed to minimize the impact of treatment on both
urinary function and body image, we also analyzed a sin-
gle body image question. The response distribution for
this item was not significantly different between the cys-
tectomy groups (Mantel-Haenszel chi-square P ¼ .40).
DISCUSSION
Using the BCI, we have shown differences in disease-
specific HRQOL among bladder cancer patients with
various levels of disease severity and managed with
standard treatments ranging from cystoscopy to radical
cystectomy. HRQOL differences between native bladder
groups and cystectomy groups were observed in urinary,
bowel, and sexual function and bother domains. Interest-
ingly, urinary function scores were significantly lower
among cystectomy patients treated with a neobladder
urinary diversion compared with those in other treat-
ment groups, including the cystectomy/ileal conduit
group. Although bother scores were also lower in the cys-
tectomy/neobladder group compared with the native
bladder groups, there was no difference in urinary bother
TABLE 3










Function 90.7y 89.2{ 86.5* 49.8*{y
Bother 95.4* 93.4{ 88.4 86.3*{
Bowel domain
Function 82.0 88.6*{ 77.6* 76.6{
Bother 93.0*y 92.3{§ 80.8*{ 85.7y§
Sexual domain
Function 45.7*y 42.2{§ 20.0*{ 25.5y§
Bother 67.4*y 71.7{§ 50.3*{ 49.9y§
BCI indicates Bladder Cancer Index; Tx, transection.
Same symbol in the same row indicates a statistically significant pairwise difference of mean scores between treatment groups (multiple-comparison adjusted P  .05).
Scores adjusted for age, gender, income, education, relationship status, and follow-up time.
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FIGURE 2. Differences in nighttime urinary leakage and control between treatment groups.
FIGURE 1. Differences in daytime urinary leakage and control between treatment groups.
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between the cystectomy groups. Similar differences
favoring the native bladder groups were seen in both the
bowel and sexual domains, indicating that the BCI is sen-
sitive in detecting a range of disease-specific HRQOL dif-
ferences between cystectomy and native bladder groups.
Although urinary, bowel, and sexual scores did vary
between the native bladder groups, the differences were
not significant. Further evaluation will be necessary to
determine if small differences between native bladder
groups are detectable with the BCI. These preliminary
data indicate that the BCI is a sensitive instrument capa-
ble of detecting therapy effects across the spectrum of
treatment modalities in bladder cancer patients with
both urinary diversions and intact bladders.
In the context of the current state of knowledge
regarding disease-specific HRQOL in bladder cancer,
our results are important. Although there has been long-
standing interest regarding the HRQOL impact of cys-
tectomy and urinary diversion,6 previous research in
this area has been limited by a lack of reliable, respon-
sive, and disease-specific HRQOL measures.7,8 The need
to address the limitations in this area of research has
been outlined by several recent reviews.3,9–11 The effort
to measure HRQOL among bladder cancer patients has
also been limited to the cystectomy population4; how-
ever, there is a substantial need to broaden the scope of
HRQOL assessment to include the majority of patients
with bladder cancer who are managed with less invasive
treatments.12 Currently, the burden of disease and the
impact of treatment are unknown for the noncystect-
omy bladder cancer population. The BCI addresses this
gap and is the first disease-specific, responsive, and reli-
able HRQOL assessment measure that can be used in all
bladder cancer patients, regardless of disease severity or
primary treatment modality.
The finding that urinary function was lower in
the cystectomy/neobladder group compared with the
cystectomy/ileal conduit group is in contrast to the
commonly held belief that continent urinary diver-
sion offers improved HRQOL outcomes compared
with incontinent urinary diversion.2 Although the
urologic community has adopted continent diversion
as a means to preserve urinary function and body
image, there is limited empirical evidence indicating
that there is an HRQOL benefit favoring continent
diversion.3,9–11 As previously indicated, much of the
uncertainty regarding a definitive benefit of continent
urinary diversion is related to limitations of HRQOL
assessment used in previous studies.3,9–11 Our results
indicate that known complications related to conti-
nent urinary diversion, such as incontinence and lack
of urinary control, particularly at night, contribute
significantly to the relatively low urinary function
scores observed among cystectomy/neobladder
patients. Interestingly, although function scores dif-
fered significantly, there was no difference in urinary
bother between the cystectomy groups, indicating
that neobladder patients adapt to functional impair-
ments. It is possible that additional unmeasured fac-
tors, such as patient expectation, preference, and
compromise between preserving anatomic urinary
function (urinating per urethra) in exchange for phys-
iology function (full urinary control), influence over-
all HRQOL. Nevertheless, these results indicate that
functional issues related to daytime and nighttime
urinary incontinence are areas that may be targeted
to improve HRQOL among cystectomy patients trea-
ted with neobladder.
Although we have shown that the BCI can discri-
minate HRQOL outcomes according to different
treatments for a broad range of bladder cancer
patients, the results concerning differences between
the cystectomy/ileal conduit and cystectomy/neo-
bladder groups should be interpreted cautiously.
Limitations of the cross-sectional design obviate
our ability to adjust for baseline quality of life and
selection bias may have also impacted our findings.
Response bias may also have been present, given
the survey component of the study. This limitation
will be addressed in a prospective study where all
subjects will be approached regarding participation
in HRQOL assessment before treatment. In addi-
tion, a larger number of subjects and a defined time
interval between treatment and HRQOL assessment
will reduce the chance of a type II error and may
reveal significant differences that we were unable to
detect.
Other study limitations were present. A lack of lon-
gitudinal follow-up assessment did not allow us to
determine the stability of HRQOL scores over time. In
addition, a lack of detailed clinical information pre-
vented adjustment for unmeasured covariates, and the
level to which factors such as the number and setting of
intravesical treatments, agent used, and exposure to
other therapies such as radiation and chemotherapy
could not be determined in this study. Furthermore, the
study did not include nonorthotopic continent urinary
diversions, and interpretation of the results should be
limited to orthotopic continent urinary diversion.
Finally, our assessment of body image was based on a
single item, and was likely not sensitive to all important
aspects of body image among bladder cancer patients.
To address this, we plan to administer a 10-item body
image scale with the BCI13 and will assess this change in
future projects.
Although measurable functional differences were
apparent using the BCI, the overall quality of life of
patients treated with continent and incontinent urinary
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diversion may not differ significantly. Whereas some
may argue that our results suggest that HRQOL is worse
in patients treated with neobladder compared with
those managed with ileal conduit, the fact that urinary
bother scores were not significantly different should
limit this interpretation. Other important motivating
factors that were not apparent from our results, such as
patient preferences, attempt to preserve body image
and anatomic voiding, and acceptance of known urinary
dysfunction may ultimately affect HRQOL outcomes in
important ways. Further evaluation and prospective
study using the BCI will improve our understanding of
disease-specific HRQOL in both cystectomy and non-
cystectomy bladder cancer patients.
Conclusions
The BCI is a disease-specific, reliable, and responsive
HRQOL assessment tool that can detect HRQOL out-
come differences between different disease stages and
treatment modalities in bladder cancer patients. It is the
first instrument developed for bladder cancer HRQOL
assessment using standard psychometric methods that
is both disease-specific and inclusive of all bladder can-
cer patients. As indicated by differences in urinary,
bowel, and sexual domain scores, the HRQOL impact of
bladder cancer management varies according to treat-
ment modality. Observed differences in urinary function
between neobladder and ileal conduit urinary diver-
sions indicate that patients with orthotopic continent
urinary diversion experience greater leakage and lack of
control, particularly at night; however, this group does
not appear to be more bothered by this relative impair-
ment in function. The results of this study indicate that
efforts to address urinary leakage and control may result
in improved HRQOL scores among patients treated with
orthotopic continent urinary diversion. Future prospec-
tive studies using the BCI will further elucidate HRQOL
outcomes and the impact of treatment among bladder
cancer patients managed with endoscopic and intra-
vesical therapies, as well as those treated with cystec-
tomy and urinary diversion.
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